DF/HCC Seminars in Oncology Series with Stefani Spranger
Date and Time
Location
Stefani Spranger, Ph.D.
Assistant Professor of Biology, Koch Institute for Integrative Cancer Research at MIT
"The goal of the Spranger lab is to understand how a range of tumor cell-intrinsic, tissue-specific and environmental factors directly impact the interaction between the cancer and the immune system. Cancer immunotherapies, first and foremost checkpoint blockade therapy (anti-CTLA4 and anti-PD-1/PD-L1), have revolutionized cancer treatment. Despite these advances only a fraction of cancer patients responds to immunotherapeutic interventions. Even for cancer types that typically show high response rates, only a fraction of patients respond. We aim to understand which tumor cell-intrinsic, tissue-macroenvironmental and environmental factors mediate resistance mechanisms against immunotherapy by affecting T cell infiltration into tumors."